Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Provided By PR Newswire
Last update: Nov 19, 2025
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735
Read more at prnewswire.com
